Needham & Company LLC Forecasts Strong Price Appreciation for Personalis (NASDAQ:PSNL) Stock

Personalis (NASDAQ:PSNL) had its price target hoisted by analysts at Needham & Company LLC from $10.00 to $12.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 32.45% from the stock’s previous close.

Several other brokerages have also issued reports on PSNL. Lake Street Capital restated a “buy” rating and set a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Guggenheim increased their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. HC Wainwright boosted their target price on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. BTIG Research upped their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Personalis presently has a consensus rating of “Moderate Buy” and an average price target of $11.14.

Personalis Price Performance

NASDAQ PSNL opened at $9.06 on Friday. The business’s fifty day moving average is $8.83 and its 200-day moving average is $7.98. The stock has a market capitalization of $804.53 million, a price-to-earnings ratio of -9.96 and a beta of 1.98. Personalis has a one year low of $2.83 and a one year high of $11.50.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. Research analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

A number of institutional investors have recently added to or reduced their stakes in PSNL. T. Rowe Price Investment Management Inc. boosted its stake in Personalis by 273.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after buying an additional 802,268 shares in the last quarter. AIGH Capital Management LLC boosted its position in shares of Personalis by 4.5% in the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after acquiring an additional 168,143 shares during the period. Aberdeen Group plc grew its stake in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its stake in Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis News Summary

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.